Circadian Rhythm Sleep Disorders Market

Circadian Rhythm Sleep Disorders Market Size and Share Forecast Outlook 2025 to 2035

The Circadian Rhythm Sleep Disorders Market is estimated to be valued at USD 2.4 billion in 2025 and is projected to reach USD 4.5 billion by 2035, registering a compound annual growth rate (CAGR) of 6.5% over the forecast period.

Quick Stats for Circadian Rhythm Sleep Disorders Market

• Circadian Rhythm Sleep Disorders Market Value (2025): USD 2.4 billion
• Circadian Rhythm Sleep Disorders Market Forecast Value (2035): USD 4.5 billion
• Circadian Rhythm Sleep Disorders Market Forecast CAGR: 6.5%
• Leading Segment in Circadian Rhythm Sleep Disorders Market in 2025: Devices (18.0%)
• Key Growth Regions in Circadian Rhythm Sleep Disorders Market: North America, Asia-Pacific, Europe
• Top Key Players in Circadian Rhythm Sleep Disorders Market: Pfizer Inc., Vanda Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sanofi S.A., Merck & Co., Inc., Eisai Co., Ltd., Jazz Pharmaceuticals plc, Koninklijke Philips N.V., ResMed Inc., Fisher & Paykel Healthcare Corporation Limited, Natus Medical Incorporated, Compumedics Limited, Becton, Dickinson and Company, Medtronic plc

Circadian Rhythm Sleep Disorders Market Key Takeaways

Metric	Value
Circadian Rhythm Sleep Disorders Market Estimated Value in (2025 E)	USD 2.4 billion
Circadian Rhythm Sleep Disorders Market Forecast Value in (2035 F)	USD 4.5 billion
Forecast CAGR (2025 to 2035)	6.5%

Why is the Circadian Rhythm Sleep Disorders Market Growing?

The Circadian Rhythm Sleep Disorders market is experiencing steady growth driven by the rising prevalence of sleep-related disorders and the growing awareness about the importance of healthy sleep patterns. In 2025, increasing recognition of sleep disorders as a significant contributor to overall health challenges has encouraged both patients and healthcare providers to adopt evidence-based treatments.

Technological advancements in sleep monitoring and intervention devices are enabling precise, personalized therapy options, while innovations in non-pharmacological treatments are providing safer alternatives to traditional medications. Investment in home care and outpatient settings has further accelerated market growth, as patients increasingly prefer treatments that can be managed outside hospital environments.

The increasing incidence of lifestyle-related sleep disruptions, along with rising stress levels and work-from-home arrangements, is contributing to demand for devices and interventions tailored to individual circadian rhythms The market outlook remains positive, supported by expanding research into sleep science, development of novel devices, and growing penetration of healthcare services in both developed and emerging regions.

Segmental Analysis

The circadian rhythm sleep disorders market is segmented by treatment type, disorder, and geographic regions. By treatment type, circadian rhythm sleep disorders market is divided into Devices and Medications. In terms of disorder, circadian rhythm sleep disorders market is classified into Delayed Sleep Phase Syndrome (DSPS), Advanced Sleep Phase Syndrome (ASPS), Irregular Sleep-Wake Disorder (ISWD), Shift Work Disorder, Free-Running Type, and Jet Lag. Regionally, the circadian rhythm sleep disorders industry is classified into North America, Latin America, Western Europe, Eastern Europe, Balkan & Baltic Countries, Russia & Belarus, Central Asia, East Asia, South Asia & Pacific, and the Middle East & Africa.

Insights into the Devices Segment

The Devices treatment type is projected to hold 18.0% of the Circadian Rhythm Sleep Disorders market revenue share in 2025, positioning it as a key contributor within treatment modalities. Growth in this segment has been driven by the increasing adoption of wearable and bedside devices that regulate light exposure and track sleep patterns to correct misaligned circadian rhythms.

The modularity and non-invasive nature of these devices have encouraged patient compliance, particularly in home care environments. In addition, technological integration with mobile applications and smart home systems has enhanced the personalization and monitoring capabilities of these devices, enabling clinicians to provide tailored interventions without frequent hospital visits.

Rising awareness among patients regarding non-drug treatment options, along with the emphasis on long-term management of sleep disorders, has further strengthened the demand for devices As research continues to highlight the benefits of light therapy, chronotherapy, and biofeedback mechanisms, the devices segment is expected to sustain growth due to its adaptability, effectiveness, and ability to complement other therapeutic interventions.

Insights into the Delayed Sleep Phase Syndrome Segment

Delayed Sleep Phase Syndrome is estimated to account for 35.0% of the Circadian Rhythm Sleep Disorders market revenue share in 2025, emerging as the leading disorder segment. This prominence is primarily driven by the rising incidence of delayed sleep onset in adolescents and adults, largely attributed to lifestyle changes, extended screen time, and irregular work schedules.

The condition’s diagnosis and treatment have benefited from advancements in sleep tracking and personalized therapy protocols, which allow precise alignment of sleep-wake cycles with natural circadian rhythms. The increasing awareness of the health consequences of untreated sleep phase disorders has prompted more patients to seek early intervention, particularly through devices and behavioral therapies.

Non-pharmacological approaches, such as light therapy and structured sleep scheduling, have become standard treatments, improving patient outcomes and adherence With expanding home care infrastructure and enhanced patient education on circadian health, the delayed sleep phase syndrome segment is expected to maintain a leading position, driven by both clinical recognition and consumer adoption of innovative sleep management solutions.

Insights into the Home Care Settings Segment

Home Care Settings are projected to hold 40.0% of the Circadian Rhythm Sleep Disorders market revenue share in 2025, establishing them as the dominant end-use segment. This leadership is being attributed to the increasing preference for patient-centered care that allows management of sleep disorders in familiar and comfortable environments.

The growth has been further supported by the availability of user-friendly, non-invasive devices, mobile sleep tracking applications, and remote monitoring technologies that enable clinicians to supervise treatment efficacy without requiring hospital visits. Rising awareness of the impact of disrupted sleep on productivity, mental health, and chronic disease management has encouraged patients and caregivers to adopt home-based interventions.

Additionally, insurance coverage and reimbursement for home care devices and therapies have enhanced accessibility and affordability The emphasis on personalized, flexible, and continuous management of circadian rhythm disorders has reinforced the attractiveness of home care solutions, while ongoing advancements in portable devices and digital health monitoring are expected to sustain growth within this segment.

Market Overview

Circadian Rhythm Sleep Disorders Market Introductoin

Circadian rhythm sleep disorders (CRSDs) are considered as the internal abnormalities of the circadian rhythms, the body internal clock. Circadian rhythm sleep disorders are caused by alterations of the central circadian timekeeping system and the external environment.

Circadian rhythm sleep disorders generally arise when a person is unable to fall asleep at a normal bedtime and affects the timing of sleep. Circadian rhythm sleep disorders are categorized into advanced sleep phase disorder (ASPS), delayed sleep phase disorder (DSPD), jet lag, shift work disorder, and free-running type.

Delayed sleep phase disorder is a very common type of circadian rhythm sleep disorders with an estimated prevalence of around 7% to 16% in the general population. Several studies estimated that about 5-10% of chronic insomnia patients have delayed sleep phase disorder.

Some of the effects that usually occur due to circadian rhythm sleep disorders are sleep loss, disrupted social schedules, insomnia, and others. Circadian rhythm sleep disorders not only impairs sleep and wake performance, but also negatively affects the functions of multiple organ systems, and increases the risk of metabolic, cardiovascular, cognitive and mood disorders.

The diagnosis of circadian rhythm sleep disorders is based on a detailed history of the patient's sleep and walking pattern. Circadian rhythm sleep disorders treatment include lifestyle changes, sleep hygiene, bright light therapy, medications, and melatonin.

Analysis of Circadian Rhythm Sleep Disorders Market By Key Countries

Country	CAGR
China	8.8%
India	8.1%
Germany	7.5%
Brazil	6.8%
USA	6.2%
UK	5.5%
Japan	4.9%

Country-wise Analysis

The Circadian Rhythm Sleep Disorders Market is expected to register a CAGR of 6.5% during the forecast period, exhibiting varied country level momentum. China leads with the highest CAGR of 8.8%, followed by India at 8.1%. Developed markets such as Germany, France, and the UK continue to expand steadily, while the USA is likely to grow at consistent rates. Japan posts the lowest CAGR at 4.9%, yet still underscores a broadly positive trajectory for the global Circadian Rhythm Sleep Disorders Market. In 2024, Germany held a dominant revenue in the Western Europe market and is expected to grow with a CAGR of 7.5%. The USA Circadian Rhythm Sleep Disorders Market is estimated to be valued at USD 892.0 million in 2025 and is anticipated to reach a valuation of USD 892.0 million by 2035. Sales are projected to rise at a CAGR of 0.0% over the forecast period between 2025 and 2035. While Japan and South Korea markets are estimated to be valued at USD 127.1 million and USD 62.7 million respectively in 2025.

Key Players in the Circadian Rhythm Sleep Disorders Market

• Pfizer Inc.
• Vanda Pharmaceuticals Inc.
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd.
• Mylan N.V.
• Sanofi S.A.
• Merck & Co., Inc.
• Eisai Co., Ltd.
• Jazz Pharmaceuticals plc
• Koninklijke Philips N.V.
• ResMed Inc.
• Fisher & Paykel Healthcare Corporation Limited
• Natus Medical Incorporated
• Compumedics Limited
• Becton, Dickinson and Company
• Medtronic plc

Scope of the Report

Item	Value
Quantitative Units	USD 2.4 Billion
Treatment Type	Devices and Medications
Disorder	Delayed Sleep Phase Syndrome (DSPS), Advanced Sleep Phase Syndrome (ASPS), Irregular Sleep-Wake Disorder (ISWD), Shift Work Disorder, Free-Running Type, and Jet Lag
Regions Covered	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Covered	United States, Canada, Germany, France, United Kingdom, China, Japan, India, Brazil, South Africa
Key Companies Profiled	Pfizer Inc., Vanda Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sanofi S.A., Merck & Co., Inc., Eisai Co., Ltd., Jazz Pharmaceuticals plc, Koninklijke Philips N.V., ResMed Inc., Fisher & Paykel Healthcare Corporation Limited, Natus Medical Incorporated, Compumedics Limited, Becton, Dickinson and Company, and Medtronic plc

Circadian Rhythm Sleep Disorders Market by Segments

Treatment Type:

• Devices
• Medications

Disorder:

• Delayed Sleep Phase Syndrome (DSPS)
• Advanced Sleep Phase Syndrome (ASPS)
• Irregular Sleep-Wake Disorder (ISWD)
• Shift Work Disorder
• Free-Running Type
• Jet Lag

Region:

• North America
  • USA
  • Canada
  • Mexico
• Latin America
  • Brazil
  • Chile
  • Rest of Latin America
• Western Europe
  • Germany
  • UK
  • Italy
  • Spain
  • France
  • Nordic
  • BENELUX
  • Rest of Western Europe
• Eastern Europe
  • Russia
  • Poland
  • Hungary
  • Balkan & Baltic
  • Rest of Eastern Europe
• East Asia
  • China
  • Japan
  • South Korea
• South Asia and Pacific
  • India
  • ASEAN
  • Australia & New Zealand
  • Rest of South Asia and Pacific
• Middle East & Africa
  • Kingdom of Saudi Arabia
  • Other GCC Countries
  • Turkiye
  • South Africa
  • Other African Union
  • Rest of Middle East & Africa